PSIL241220C11000
- 0.00
- 0.000.00%
ADVISORSHARES PSYCHEDELICS ETF Newsroom
Needham Reiterates Hold on Neurocrine Biosciencesto Hold
MindMed To Be Added To The Nasdaq Biotechnology Index, Effective At Market Open On December 23, 2024
As Small-caps Ride the Trump Wave, Here Are the Best & Worst Such Stocks as per SA Quant
Mind Medicine Analyst Ratings
Summit Therapeutics Shares Are Trading Higher. The Stock May Be Moving in Sympathy With Neurocrine Biosciences Which Received FDA Approval for CRESNESSITY.
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $148 Price Target
Stifel Maintains Hold on Sage Therapeutics, Lowers Price Target to $6
Neurocrine Biosciences Analyst Ratings
Reported Friday, Neurocrine Biosciences' CRENESSITY Receives FDA Approval, Revolutionizing Treatment For Classic Congenital Adrenal Hyperplasia
Intra-Cellular Therapies Presents Data From The CAPLYTA Adjunctive MDD Phase 3 Program At The American College Of Neuropsychopharmacology Annual Meeting; Data Shows Robust Remission And Response Efficacy Rates In Patients Taking CAPLYTA, As Well As...
"Laggard" Stocks With Expanding FCF Margins and Attractive FCF Yields – Goldman
MindMed Awarded Innovation Passport Designation By United Kingdom Innovative Licensing And Access Pathway Steering Group For MM120 Orally Disintegrating Tablet For Generalized Anxiety Disorder
Screening For Black Friday Bargains In The Stock Market
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $19 Price Target
TD Cowen Maintains Hold on Sage Therapeutics, Lowers Price Target to $9
This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics